Compare DexCom, Inc. (DXCM) vs NetApp Inc. (NTAP) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

NetApp (NTAP) trades at $157.82, down 9.6% in the last session, but maintains strong profitability with an 18.4% net margin and has beaten EPS estimates for three consecutive quarters. The stock shows a bullish technical signal with moving averages supporting upside, while analyst consensus targets $167.45. Recent news highlights AI infrastructure demand and a new NFL partnership, reinforcing growth prospects amid a solid cash flow position.

Outlook remains positive driven by AI-driven storage demand and recurring revenue strength, though risks include competitive pressures and debt levels. With a high ROE of 106.7% and institutional buy ratings at 36.6%, NTAP offers growth potential, but investors should monitor execution on Q2 2026 earnings and macroeconomic headwinds.